NasdaqGM:NTLABiotechs
Assessing Intellia Therapeutics (NTLA) Valuation After FDA Hold Lift And New Gene Editing Data
The FDA’s decision to lift the clinical hold on Intellia Therapeutics (NTLA) MAGNITUDE Phase 3 trial and the new hereditary angioedema data for lonvoguran ziclumeran have refocused attention on the company’s gene editing pipeline.
See our latest analysis for Intellia Therapeutics.
At a share price of $13.44, Intellia has seen a 39.85% 90 day share price return and a 45.93% year to date share price return. The 5 year total shareholder return of 79.49% and 3 year total shareholder return of...